跳至主要内容
临床试验/NCT07575360
NCT07575360已完成不适用

Conversion to Endoscopic Ultrasound-Guided Gallbladder Drainage (EUS-GBD) Versus Standard Management of High-Risk Surgical Patients Who Underwent Percutaneous Trans-Hepatic Gallbladder Drainage (PT-GBD) for Acute Cholecystitis

University of Bologna1 个研究点 分布在 1 个国家目标入组 484 人开始时间: 2024年4月1日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
484
试验地点
1

研究概览

简要总结

Acute cholecystitis in high-risk surgical patients is commonly managed with percutaneous trans-hepatic gallbladder drainage (PT-GBD). However, long-term adverse events, tube dysfunction, and recurrent cholecystitis remain significant concerns. This retrospective multicenter observational study compares long-term outcomes of conversion from PT-GBD to endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with lumen-apposing metal stents (LAMS) versus standard management in high-risk surgical patients with acute cholecystitis.

详细描述

Acute cholecystitis is a common and potentially severe condition that often requires timely intervention, particularly in high-risk surgical patients who are not suitable candidates for cholecystectomy. In this population, percutaneous trans-hepatic gallbladder drainage (PT-GBD) is widely used as an effective minimally invasive treatment, providing rapid clinical improvement and high technical success rates. However, despite its short-term efficacy, PT-GBD is associated with significant long-term limitations, including tube dysfunction or dislodgement, patient discomfort related to the external catheter, and a relatively high incidence of recurrent cholecystitis and other adverse events.

Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using lumen-apposing metal stents (LAMS) has emerged as an alternative minimally invasive approach that allows internalization of gallbladder drainage. This technique has the potential to improve patient quality of life, reduce catheter-related complications, and decrease the incidence of recurrent biliary events. Conversion from PT-GBD to EUS-GBD has been proposed as a strategy to overcome the limitations of long-term percutaneous drainage. Preliminary evidence suggests that such a conversion is technically feasible and associated with favorable clinical outcomes, including reduced adverse events and improved long-term management.

Nevertheless, the available literature is limited, and comparative data between conversion to EUS-GBD using LAMS and standard management after PT-GBD are scarce. In particular, only a limited number of studies have specifically evaluated outcomes following conversion with LAMS, and no large comparative studies have definitively assessed its impact on long-term adverse events and clinical outcomes.

This multicenter retrospective observational study aims to compare the long-term outcomes of two management strategies in high-risk surgical patients with acute cholecystitis who previously underwent PT-GBD: (1) conversion to EUS-GBD using LAMS and (2) standard management without conversion. All consecutive eligible patients treated with PT-GBD will be retrospectively identified and included according to predefined inclusion and exclusion criteria.

The primary objective of the study is to evaluate the incidence of adverse events at 1 year in patients undergoing PT-GBD to EUS-GBD conversion compared with those receiving standard management. Secondary objectives include the assessment of technical success, clinical success, procedural adverse events, 30-day adverse events, 1-year incidence of stent dysfunction, biliary adverse events, recurrent cholecystitis, biliary reintervention rate, readmission rate, biliary-related mortality, and overall survival.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years
  • Patients considered unfit for surgery after multidisciplinary discussion
  • Patients who underwent PT-GBD for acute cholecystitis

排除标准

  • Patients with improved general conditions who become fit for laparoscopic cholecystectomy
  • Use of anticoagulants that cannot be discontinued
  • Coagulation and/or platelet hereditary disorders and/or INR >1.5, PLT <50,000
  • Absolute contraindication for EUS-GBD
  • Post-surgical altered upper gastrointestinal anatomy
  • Malignant biliary obstruction

研究者

发起方
University of Bologna
申办方类型
Other
责任方
Principal Investigator
主要研究者

Pietro Fusaroli

Associate Professor

University of Bologna

研究点 (1)

Loading locations...

相似试验